The innovative artificial intelligence tool, SCORPIO, developed by Memorial Sloan Kettering Cancer Center and Mount Sinai, is revolutionizing cancer care by enhancing immunotherapy decision-making. This groundbreaking tool analyzes routine blood tests, like complete blood counts, instead of relying on expensive tumor biopsies or genetic sequencing. SCORPIO promises to make precision cancer treatment more accessible and affordable globally, targeting patients most likely to benefit from immunotherapy, including immune checkpoint inhibitors.
Tested on nearly 10,000 patients across 21 cancer types, SCORPIO outperformed existing FDA-approved biomarkers, efficiently linking routine data to past patient responses. Importantly, it requires no additional costly tests, thus reducing financial and logistical burdens. Although SCORPIO isn’t yet in clinical use, researchers are actively optimizing its implementation for widespread application. If successful, SCORPIO will enable personalized immunotherapy decisions in both advanced oncology centers and resource-limited settings, paving the way for equitable cancer care worldwide.
Source link
